Xyphos Biosciences, Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Poseida Therapeutics Inc., have entered into a research collaboration and license agreement to develop novel convertibleCAR programs by combining the cell therapy platforms of each company.
 
Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. In oncology, its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors that address patient populations with high unmet medical need. Meanwhile, Xyphos utilizes a novel and proprietary ACCEL technology platform that uses its convertibleCAR (convertible Chimeric Antigen Receptor) in combination with proprietary MicAbodies to target tumor cells.
 
Under the terms of the agreement, the companies plan to combine Poseida’s proprietary allogeneic CAR-T platform with Xyphos’ ACCEL technology to create one Poseida-developed CAR-T construct to form the basis of two convertibleCAR product candidates targeting solid tumors. Xyphos will reimburse Poseida for costs incurred as part of the research agreement and will be responsible for the development and future commercialization of products generated from the collaboration.
 
Poseida will receive $50 million upfront plus potential development and sales milestones and contingency payments of up to $550 million in total. Additionally, Poseida is eligible for up to low double digit tiered royalties as a percentage of net sales.
 
Kristin Yarema, Ph.D., President and CEO of Poseida, said, “We are excited to expand our relationship with Astellas, where we share a vision that cutting edge, off the shelf cell therapies can address significant unmet needs of patients with solid tumor malignancies.”
 
Adam Pearson, Chief Strategy Officer (CStO) of Astellas, added, “By combining the ACCEL platform with Poseida’s elegant and cutting-edge genetic editing platforms, we believe the collaboration will bring synergies between the two companies’ breakthrough research and will ultimately lead to expansion of Astellas’ portfolio and to delivery of innovative CAR-T cell therapies to cancer patients.”